secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0000950170-24-136042
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Therapeutics appoints Eric A. Hughes, M.D., Ph.D. to Board of Directors
--------------------------------------------------------------------------------

- Dr. Hughes is Executive VP, Global R&D and Chief Medical Officer at Teva Pharmaceuticals; previously at Vertex, Novartis, BMS.
- Granted option to purchase 44,200 shares vesting monthly over 36 months; annual director fee of $40,000.
- Also eligible for annual stock option grants of 22,100 shares after each annual meeting starting 2025.
- Board determined Dr. Hughes is independent under Nasdaq standards; serves as Class III director until 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024136042/0000950170-24-136042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024136042/glue-20241211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-136042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer